Premium Nahrungsergänzungsmittel | artgerecht

Bruton-Gitlin Syndrome: Causes, Symptoms & Treatment

Bruton-Gitlin Syndrome is a rare inherited immune deficiency in which B cells are absent and no antibodies are produced. It affects almost exclusively boys.

Regular tips about health Regular tips about health

Things worth knowing about "Bruton-Gitlin Syndrome"

Bruton-Gitlin Syndrome is a rare inherited immune deficiency in which B cells are absent and no antibodies are produced. It affects almost exclusively boys.

What is Bruton-Gitlin Syndrome?

Bruton-Gitlin Syndrome, also known as X-linked agammaglobulinemia (XLA), is a rare congenital disorder of the immune system. It was first described in 1952 by the American physician Ogden Bruton and is classified as a primary immunodeficiency. In this condition, functional B lymphocytes (B cells) are almost completely absent from the blood, which means the body cannot produce antibodies (immunoglobulins). Because the responsible gene is located on the X chromosome, the syndrome affects almost exclusively males.

Causes

Bruton-Gitlin Syndrome is caused by a mutation in the BTK gene (Bruton tyrosine kinase gene), located on the X chromosome. The BTK gene provides instructions for producing an enzyme called Bruton tyrosine kinase, which is essential for the normal development and maturation of B lymphocytes. Without this functional enzyme, precursor cells in the bone marrow cannot develop into mature B cells. Females carry two X chromosomes, so a faulty copy is typically compensated by the second, healthy copy. Males, however, have only one X chromosome and therefore develop the disease when a mutation is present.

Symptoms

Newborns are initially protected by maternal antibodies transferred through the placenta. Once these decline -- typically between 6 and 12 months of age -- the first symptoms usually appear:

Recurrent bacterial infections, particularly of the respiratory tract (e.g., pneumonia, bronchitis, sinusitis, otitis media)
Infections caused by encapsulated bacteria such as Streptococcus pneumoniae or Haemophilus influenzae
Chronic diarrhea, often due to Giardia lamblia
Absent or markedly reduced lymph nodes and tonsils
Poor growth and failure to thrive in childhood

Most viral infections are handled normally because T cell immunity remains intact. Notable exceptions include certain enteroviruses and the poliovirus, to which affected individuals are particularly susceptible.

Diagnosis

Diagnosis is established through the following investigations:

Blood count and immunophenotyping: Demonstration of markedly reduced or absent B cells in peripheral blood
Immunoglobulin measurement: Very low or undetectable levels of all immunoglobulin classes (IgG, IgA, IgM, IgE)
Genetic testing: Identification of a BTK gene mutation to confirm the diagnosis
Family history: Other affected male relatives are often identified

Early diagnosis is critical to prevent serious infectious complications.

Treatment

A cure for Bruton-Gitlin Syndrome is currently only possible through hematopoietic stem cell transplantation, which is reserved for selected cases. The standard treatment consists of lifelong antibody replacement therapy:

Immunoglobulin replacement therapy (IgG substitution): Regular administration of immunoglobulins, either intravenously (every 3 to 4 weeks) or subcutaneously (weekly or biweekly), to compensate for the missing antibody protection
Antibiotic therapy: Used to treat acute bacterial infections and, in certain situations, as prophylaxis
Regular monitoring: Surveillance of immunoglobulin levels, lung function, and general health

With consistent treatment, affected individuals can lead largely normal lives. However, long-term complications such as chronic lung disease or neurological problems from enteroviruses can still occur.

References

Ochs HD, Smith CI, Puck JM (eds.) - Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. Oxford University Press, 3rd edition, 2014.
Picard C et al. - International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology, 2018. PubMed PMID: 29226302.
European Society for Immunodeficiencies (ESID) - ESID Registry and Clinical Guidelines for XLA. https://esid.org (accessed 2024).

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.